Grifols is expected to report Q2 2026 revenue of $2.17 billion and an EPS of $0.27, with the stock’s current price of $8.25 trading significantly below the average analyst target of $10.87. The primary story investors are watching is the company’s Free Cash Flow (FCF) generation as a indicator of its progress toward aggressive 2026 deleveraging targets.
Supporting this focus, management has reaffirmed its full-year FCF guidance of €500-575 million, which is vital for reducing the current 4.2x net leverage ratio. Recent results have shown stabilizing plasma collection costs and a robust turnaround in the Biopharma segment, though market sentiment remains wary of previous governance concerns.